The Gene Therapy Program (GTP) at the University of Pennsylvania (UPenn) continues to provide critical technical resources and leadership to the evolving field of cell and gene therapy for genetic diseases that include CF. The NIDDK P30 Center currently entitled Molecular Therapy for Cystic Fibrosis (CF) remains the flagship of the GTP, having been in existence for the entire 20 years that the PI (James M. Wilson) has been at UPenn. For this new cycle, the original single center has been transformed into a four center consortium. The main theme of the Center [Gene Therapy Program - CF Translational Research Consortium (GTP - CFTRC)] is the progression of molecular therapies into proof-of-concept phase 1 clinical trials. The GTP - CFTRC consists of four renowned institutions with a long-standing history in basic and translational CF research: UPenn (Wilson), University of Massachusetts Medical School (Flotte), Johns Hopkins University (Cebotaru/Guggino) and the United Kingdom CF Gene Therapy Consortium (Alton). Each of these centers brings with it experience in vector development, animal models, airway gene delivery, design and support of IND-enabling studies and progression into clinical trials. The outstanding success of the Pilot and Feasibility Program since its inception in 1993 reinforced the importance of innovative research in advancing the field of CF. It also prompted the GTP - CFTRC to increase its commitment to the Pilot and Feasibility Program by proposing, in this renewal, four applications for funding. The outstanding academic environment at the four centers of the GTP - CFTRC, as well as the highly respected research faculty, will allow for the conduct of innovative research in CF through the well-documented mechanism of collaboration that remains the essence of our consortium.

Public Health Relevance

For this new cycle, the original NIDDK P30 Center currently entitled 'Molecular Therapy for Cystic Fibrosis (CF)' has been transformed into a consortium consisting of four renowned institutions with a long-standing history in basic and translational CF research: UPenn, University of Massachusetts Medical School, Johns Hopkins University and the United Kingdom CF Gene Therapy Consortium. Each of these centers brings with it experience in vector development, animal models, airway gene delivery, design and support of IND-enabling studies and progression into clinical trials to support the mission of our Center which is innovative translational research for CF therapies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
2P30DK047757-21
Application #
8875353
Study Section
Special Emphasis Panel (ZDK1)
Program Officer
Eggerman, Thomas L
Project Start
1997-09-30
Project End
2018-03-31
Budget Start
2015-05-13
Budget End
2016-03-31
Support Year
21
Fiscal Year
2015
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Pathology
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Svidritskiy, Egor; Korostelev, Andrei A (2018) Conformational Control of Translation Termination on the 70S Ribosome. Structure 26:821-828.e3
Svidritskiy, Egor; Korostelev, Andrei A (2018) Mechanism of Inhibition of Translation Termination by Blasticidin S. J Mol Biol 430:591-593
Gurda, Brittney L; De Guilhem De Lataillade, Adrien; Bell, Peter et al. (2016) Evaluation of AAV-mediated Gene Therapy for Central Nervous System Disease in Canine Mucopolysaccharidosis VII. Mol Ther 24:206-216
Svidritskiy, Egor; Madireddy, Rohini; Korostelev, Andrei A (2016) Structural Basis for Translation Termination on a Pseudouridylated Stop Codon. J Mol Biol 428:2228-36
Greig, Jenny A; Calcedo, Roberto; Grant, Rebecca L et al. (2016) Intramuscular administration of AAV overcomes pre-existing neutralizing antibodies in rhesus macaques. Vaccine 34:6323-6329
McClain, Lauren E; Davey, Marcus G; Zoltick, Phillip W et al. (2016) Vector serotype screening for use in ovine perinatal lung gene therapy. J Pediatr Surg 51:879-84
Calcedo, Roberto; Wilson, James M (2016) AAV Natural Infection Induces Broad Cross-Neutralizing Antibody Responses to Multiple AAV Serotypes in Chimpanzees. Hum Gene Ther Clin Dev 27:79-82
Svidritskiy, Egor; Korostelev, Andrei A (2015) Ribosome Structure Reveals Preservation of Active Sites in the Presence of a P-Site Wobble Mismatch. Structure 23:2155-61
Wang, Lili; Bell, Peter; Somanathan, Suryanarayan et al. (2015) Comparative Study of Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids. Mol Ther 23:1877-87
Calcedo, Roberto; Franco, Judith; Qin, Qiuyue et al. (2015) Preexisting Neutralizing Antibodies to Adeno-Associated Virus Capsids in Large Animals Other Than Monkeys May Confound In Vivo Gene Therapy Studies. Hum Gene Ther Methods 26:103-5

Showing the most recent 10 out of 231 publications